Altimmune to Announce Third Quarter 2020 Financial Results on November 10

Rhea-AI Summary

Altimmune, Inc. (Nasdaq: ALT) announced it will release its third quarter 2020 financial results on November 10, 2020. A conference call for investors will follow at 8:30 a.m. ET on the same day, where management will discuss the financial results and provide a business update. The company, focused on developing intranasal vaccines and therapies, has a diverse pipeline including products for COVID-19, anthrax, and liver disease. For more details, investors can access the conference call via a webcast.

Positive

• Diverse pipeline including vaccines for COVID-19 and other diseases.

Negative

• None.

GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.

Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update.

Conference Call Details

Date:	Tuesday, November 10th
Time:	8:30 am Eastern Time
Domestic:	877-300-8521
International:	412-317-6026
Conference ID:	10149733
Webcast:	http://public.viavid.com/index.php?id=142319

About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Investor Contacts:
Will Brown		Ashley R. Robinson
Chief Financial Officer		LifeSci Advisors, LLC
Phone: 240-654-1450		617-430-7577
wbrown@altimmune.com		arr@lifesciadvisors.com
Media Contacts:
Warren Rizzi
Sard Verbinnen & Co.
Phone: 212-687-8080
altimmune-svc@sardverb.com

FAQ

When will Altimmune release its third quarter 2020 financial results?

Altimmune will release its third quarter 2020 financial results on November 10, 2020.

What time is the Altimmune investor conference call?

The investor conference call for Altimmune is scheduled for 8:30 a.m. ET on November 10, 2020.

What is Altimmune's focus in their product pipeline?

Altimmune focuses on developing intranasal vaccines, immune modulating therapies, and treatments for liver disease.

How can investors access the Altimmune conference call?

Investors can access the Altimmune conference call via a webcast at the provided link in the press release.